Skip to main content
Top
Published in: Pediatric Cardiology 6/2015

01-08-2015 | Original Article

Early Appearance of Principal Symptoms of Kawasaki Disease is a Risk Factor for Intravenous Immunoglobulin Resistance

Authors: Miyu Tajima, Yusuke Shiozawa, Jiro Kagawa

Published in: Pediatric Cardiology | Issue 6/2015

Login to get access

Abstract

It is difficult to accurately predict treatment resistance in Kawasaki disease (KD). Patients considered to be low-risk cases often develop resistance to intravenous immunoglobulin (IVIG). We herein examined whether information from the clinical course of KD could improve the prediction accuracy of a previously reported risk score. We retrospectively reviewed the clinical records of 100 KD patients. The clinical characteristics and laboratory data were compared between IVIG-sensitive and IVIG-resistant patients and also between patients with and without coronary artery aneurysm (CAA). The total incidence of IVIG resistance and CAA development was 34 and 13 %, respectively. Multiple regression analysis identified the early appearance of principal symptoms (≤day 2 of the illness) as a risk factor for IVIG resistance (OR 2.88, 95 % CI 1.11–7.44, p = 0.0041), whereas delayed IVIG administration (≥day 6) (OR 2.23, 95 % CI 0.66–7.64, p = 0.018) and IVIG resistance (OR 9.05, 95 % CI 2.27–36.10, p = 0.015) were independent predictors for CAA development. The addition of the first appearance day of principal symptoms into a previously reported scoring system improved its prediction accuracy for IVIG resistance. KD patients who had presented with any principal symptoms within 2 days of fever onset were at a high risk for IVIG resistance regardless of previously reported risk score. A careful medical history-taking that is focused on the clinical course enables a better prediction of IVIG resistance.
Literature
2.
8.
go back to reference Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A (2012) Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 379(9826):1613–1620. doi:10.1016/S0140-6736(11)61930-2 PubMedCrossRef Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A (2012) Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 379(9826):1613–1620. doi:10.​1016/​S0140-6736(11)61930-2 PubMedCrossRef
11.
go back to reference Moore A, Harnden A, Mayon-White R (2014) Recognising Kawasaki disease in UK primary care: a descriptive study using the clinical practice research datalink. Br J Gen Pract J R Coll Gen Pract 64(625):e477–e483. doi:10.3399/bjgp14X680953 CrossRef Moore A, Harnden A, Mayon-White R (2014) Recognising Kawasaki disease in UK primary care: a descriptive study using the clinical practice research datalink. Br J Gen Pract J R Coll Gen Pract 64(625):e477–e483. doi:10.​3399/​bjgp14X680953 CrossRef
12.
go back to reference Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S (2012) Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. J Rheumatol 39(4):864–867. doi:10.3899/jrheum.110877 PubMedCrossRef Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S (2012) Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. J Rheumatol 39(4):864–867. doi:10.​3899/​jrheum.​110877 PubMedCrossRef
13.
go back to reference Nakamura Y, Aso E, Yashiro M, Tsuboi S, Kojo T, Aoyama Y, Kotani K, Uehara R, Yanagawa H (2013) Mortality among Japanese with a history of Kawasaki disease: results at the end of 2009. J Epidemiol 23(6):429–434PubMedCrossRef Nakamura Y, Aso E, Yashiro M, Tsuboi S, Kojo T, Aoyama Y, Kotani K, Uehara R, Yanagawa H (2013) Mortality among Japanese with a history of Kawasaki disease: results at the end of 2009. J Epidemiol 23(6):429–434PubMedCrossRef
14.
go back to reference Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young. Am Heart Assoc Circ 110(17):2747–2771. doi:10.1161/01.CIR.0000145143.19711.78 Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young. Am Heart Assoc Circ 110(17):2747–2771. doi:10.​1161/​01.​CIR.​0000145143.​19711.​78
16.
go back to reference Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, Kogaki S, Hara J (2007) Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 166(2):131–137. doi:10.1007/s00431-006-0223-z PubMedCrossRef Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, Kogaki S, Hara J (2007) Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 166(2):131–137. doi:10.​1007/​s00431-006-0223-z PubMedCrossRef
17.
20.
23.
go back to reference Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC (2014) Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 383(9930):1731–1738. doi:10.1016/S0140-6736(13)62298-9 PubMedCrossRef Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC (2014) Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 383(9930):1731–1738. doi:10.​1016/​S0140-6736(13)62298-9 PubMedCrossRef
24.
go back to reference Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, Qi Y, Xie C, Zhang Y (2013) Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease. Arthritis Rheum 65(3):805–814. doi:10.1002/art.37815 PubMedCrossRef Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, Qi Y, Xie C, Zhang Y (2013) Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease. Arthritis Rheum 65(3):805–814. doi:10.​1002/​art.​37815 PubMedCrossRef
Metadata
Title
Early Appearance of Principal Symptoms of Kawasaki Disease is a Risk Factor for Intravenous Immunoglobulin Resistance
Authors
Miyu Tajima
Yusuke Shiozawa
Jiro Kagawa
Publication date
01-08-2015
Publisher
Springer US
Published in
Pediatric Cardiology / Issue 6/2015
Print ISSN: 0172-0643
Electronic ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-015-1136-2

Other articles of this Issue 6/2015

Pediatric Cardiology 6/2015 Go to the issue